Aimmune Therapeutics (AIMT) Reports Licensing of Exclusive Worldwide Rights to Xencor (XNCR) XmAb7195 for Development of Next-Generation Food Allergy Treatments

Aimmune Therapeutics (AIMT) PT Raised to $34 at Credit Suisse

Credit Suisse analyst Evan Seigerman raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $34.00 (from $30.00) while maintaining a Neutral rating.... More

Aimmune Therapeutics (AIMT) PT Raised to $81 at Wedbush

Wedbush analyst Liana Moussatos raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $81.00 (from $79.00) while maintaining a Outperform rating.

Pre-Open Movers 02/03: (INSM) (AIMT) (GILD) Higher; (NKTR) (CHKP) (NOC) Lower (more...)

Today's Pre-Open Movers

Insmed Incorporated (Nasdaq: INSM) 47.2% HIGHER; announced positive top-line results from its global, randomized, double-blind placebo-controlled Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of INS1007 administered once daily in adults with non-cystic fibrosis bronchiectasis (NCFBE). INS1007 is a novel, oral, selective, reversible inhibitor of dipeptidyl peptidase 1 (DPP1).

CTI BioPharma Corp. (Nasdaq: CTIC) 17.7% HIGHER; today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights... More

Aimmune Therapeutics (AIMT) PT Raised to $70 at Stifel

Stifel analyst Derek Archilia raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $70.00 (from $62.00) while maintaining a Hold rating.... More

Aimmune Therapeutics (AIMT) Confirms FDA Approves its PALFORZIA as First Treatment for Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT) announced that the U.S. Food and Drug Administration (FDA) approved PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. PALFORZIA is the first approved treatment for patients with peanut allergy. It is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial dose escalation may be administered to patients aged 4 through 17 years. Up-dosing and maintenance may be continued in patients 4 years of age and... More

Aimmune Therapeutics (AIMT) PT Raised to $44 at JMP Securities

JMP Securities analyst Liisa Bayko raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $44.00 (from $40.00) while maintaining a Market Outperform rating.... More